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Abstract
The development of protective vaccines against many difficult infectious pathogens will necessitate the induction of
effective antibody responses. Here we assess humoral immune responses against two antigens from the blood-stage
merozoite of the Plasmodium falciparum human malaria parasite – MSP1 and AMA1. These antigens were delivered to
healthy malaria-naı̈ve adult volunteers in Phase Ia clinical trials using recombinant replication-deficient viral vectors –
ChAd63 to prime the immune response and MVA to boost. In subsequent Phase IIa clinical trials, immunized volunteers
underwent controlled human malaria infection (CHMI) with P. falciparum to assess vaccine efficacy, whereby all but one
volunteer developed low-density blood-stage parasitemia. Here we assess serum antibody responses against both the MSP1
and AMA1 antigens following i) ChAd63-MVA immunization, ii) immunization and CHMI, and iii) primary malaria exposure in
the context of CHMI in unimmunized control volunteers. Responses were also assessed in a cohort of naturally-immune
Kenyan adults to provide comparison with those induced by a lifetime of natural malaria exposure. Serum antibody
responses against MSP1 and AMA1 were characterized in terms of i) total IgG responses before and after CHMI, ii) responses
to allelic variants of MSP1 and AMA1, iii) functional growth inhibitory activity (GIA), iv) IgG avidity, and v) isotype responses
(IgG1-4, IgA and IgM). These data provide the first in-depth assessment of the quality of adenovirus-MVA vaccine-induced
antibody responses in humans, along with assessment of how these responses are modulated by subsequent low-density
parasite exposure. Notable differences were observed in qualitative aspects of the human antibody responses against these
malaria antigens depending on the means of their induction and/or exposure of the host to the malaria parasite. Given the
continued clinical development of viral vectored vaccines for malaria and a range of other diseases targets, these data
should help to guide further immuno-monitoring studies of vaccine-induced human antibody responses.
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Introduction
Plasmodium falciparum is the preeminent cause of human
malaria disease and a leading example of a parasite with a
complex multi-host multi-stage lifecycle where a number of steps
in the infectious process have been shown to be antibody-
susceptible. These include the invasion of liver cells by sporozoites
delivered from the mosquito bite; the invasion of red blood cells
(RBC) by merozoites; clearance of infected RBC; and sexual-stage
development within the blood meal inside the mosquito midgut
[1]. However, despite tremendous efforts, the development of a
highly effective subunit vaccine against infection, disease or
transmission has proved an elusive goal, and P. falciparum
continues to exert a huge burden on global public health in terms
of morbidity and mortality [2], as well as financially in terms of
maintaining effective control and intervention measures [3]. Such
difficulties, with regard to subunit vaccine development have
arisen through a variety of reasons, including factors relating to the
complex biology of the parasite’s lifecycle coupled with an
incomplete understanding of protective immune effector mecha-
nisms that function in vivo in humans [4].
One leading strategy for many years has sought to develop an
effective antibody-inducing vaccine against the blood-stage mer-
ozoite, seeking to neutralize RBC invasion [5]. For a number of
decades, merozoite surface protein 1 (MSP1) [6] and apical
membrane antigen 1 (AMA1) [7] have been assessed as leading
subunit vaccine candidate antigens – both are expressed by the
invasive blood-stage merozoite, with evidence they are also present
at the late liver-stage [8] or sporozoite stage [9] of the parasite
lifecycle. These antigens, most often delivered as antibody-
inducing recombinant protein formulated in adjuvant, have shown
disappointing levels of efficacy in Phase IIa/b clinical trials
[5,10,11], although one AMA1 formulation was reported to show
strain-specific efficacy in a Phase IIb field trial in Malian children
[12]. Consequently, a number of researchers within the field have
argued that an effective blood-stage vaccine would in fact
necessitate the induction of T cell responses, in conjunction with
antibody responses, in order to achieve protection [13]. In more
recent years, recombinant simian adenoviral and poxviral
vectored vaccines have been developed as a highly immunogenic
delivery platform with a favourable safety profile for human use
[14–16]. In particular the use of recombinant adenovirus vectors
to prime immune responses, followed by immunization with a
recombinant poxvirus to boost immune responses, has emerged as
a leading strategy across multiple fields including various infectious
diseases and cancer. Although traditionally regarded as a platform
for inducing strong cellular immunity, this specific vectored
vaccine approach has also proved highly suited for antibody
induction, so long as the transgenes are designed and the vectors
are deployed in a suitable manner [17,18].
Recently we assessed this approach for targeting the blood-stage
malaria antigens P. falciparum MSP1 and AMA1. In a series of
Phase Ia clinical trials, we demonstrated that the use of a
recombinant chimpanzee adenovirus serotype 63 (ChAd63) prime,
followed by a boost with the recombinant orthopoxvirus, modified
vaccinia virus Ankara (MVA), was safe in healthy UK adults and
capable of inducing strong cellular and humoral immune
responses against both antigens [19,20]. However, in a subsequent
series of Phase IIa clinical trials, where immunized volunteers were
exposed to five infectious mosquito bites, almost no vaccine
efficacy was observed with only one volunteer protected who had
been co-immunized with the vectors encoding MSP1 and AMA1
[21]. Nevertheless, the use of the controlled human malaria
infection (CHMI) model in these studies did allow for the impact
of blood-stage parasite exposure to be assessed on vaccine-induced
immune responses in non-protected volunteers. Moreover, the
adenovirus-MVA regimen remains a leading platform in clinical
development for a wide range of disease indications and
pathogens, including other stages of the malaria parasite lifecycle
[22,23], human immunodeficiency virus-1 (HIV-1) [24], hepatitis
C virus [25], leishmaniasis [26] and cancer amongst others. In a
growing number of cases, it is likely that antibodies, in conjunction
with cellular immunity, may contribute to effective immunity. We
have previously reported in detail the cellular immune responses
(T cell and B cell) induced by these vaccines, and the impact of
CHMI on these responses [27,28]. Here we now sought to
characterize humoral antibody immune responses in humans in
much greater detail following ChAd63-MVA immunization with
two different antigens including assessment of serum antibody
avidity and isotype profiles. We also explored the impact of CHMI
on vaccine-induced antibody titers, avidity and isotype profiles and
provide comparison to de novo antigen-specific responses induced
in control volunteers as opposed to those induced by a lifetime of
exposure in naturally-immune Kenyan adults. These data provide
the first in-depth assessment of the quality of adenovirus-MVA
vaccine-induced antibody responses in humans, along with
assessment of how these responses can be modulated by
subsequent parasite exposure.
Materials and Methods
Immunization Groups and Serum Samples
Serum samples used throughout this study were obtained from
Phase Ia safety and immunogenicity clinical trials for the MSP1
[19] and AMA1 [20] candidate vaccines, or from Phase IIa
efficacy studies where immunized and non-immunized infectivity
control volunteers underwent CHMI with vaccine homologous P.
falciparum 3D7 clone sporozoites delivered by five infectious
mosquito bites. In the case of the Phase IIa studies, vaccinated
volunteers were immunized with vaccines encoding MSP1, AMA1
or the liver-stage malaria antigen ME-TRAP (a multi-epitope
string fused to the thrombospondin-related adhesion protein) [29]
either administered alone, or co-administered together at separate
sites (MSP1+AMA1 or MSP1+ME-TRAP) [21,22]. Outlines of
the immunization and bleed schedules for each type of trial are
shown in Figure S1. In all cases, the antigens were separately
delivered by a heterologous prime-boost immunization regimen
consisting of a priming intramuscular (i.m.) vaccination with a
recombinant replication-deficient ChAd63 vector (doses ranging
from 56109–561010 viral particles (vp)), followed eight weeks later
by a boosting vaccination i.m. with the MVA vector (doses ranging
from 16108–56108 plaque forming units (pfu)) recombinant for
the same antigen, all as previously described [19–22].
All necessary ethical approvals (from the UK Gene Therapy
Advisory Committee, Oxfordshire Research Ethics Committee or
Berkshire Research Ethics Committee) and regulatory approvals
(from the UK Medicines and Healthcare products Regulatory
Agency, MHRA) were granted as previously described, and the
four trials were registered with ClinicalTrials.gov (NCT01095055;
NCT01003314; NCT01142765; and NCT00890760) [19–22]. All
volunteers gave written informed consent prior to participation,
and the studies were conducted according to the principles of the
Declaration of Helsinki and in accordance with Good Clinical
Practice (GCP). All volunteers participating in these clinical trials
gave consent for samples to be used for exploratory immunology
analysis. Volunteer information was anonymized for all immuno-
logical analyses. Serum samples from the trials were all prepared
and frozen according to a previously described protocol [19].
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Figure 1. Assessment of IgG antibody responses post-CHMI. Mean anti-MSP119 serum IgG responses were assessed over time by ELISA in a
Phase IIa CHMI trial [21]. Dashed vertical lines represent: day 72 (d72) = day of CHMI; and d85 = nominal day of diagnosis. The first follow-up time-
point after CHMI = day 107 (dC+35). (A) VAC039: MSP1 vaccinees (n = 8–9 depending on time-point assessed); AMA1-only vaccinees (n = 9); MSP1+
AMA1 vaccinees (n = 8) plus one volunteer who was steriley protected in this group (dashed line); MSP1+ME-TRAP (n = 10); and infectivity controls
(n = 6). The second Phase IIa CHMI trial with MSP1 vaccinees (VAC037) is shown in Figure S2. (B) Individual and median anti-MSP119 serum IgG
responses are shown for MSP1 vaccinees at the peak after the MVA boost (open symbols, n = 17) [19,21] and at dC+35 following CHMI (closed
symbols, n = 11) [21]; at dC+35 for 18 infectivity control volunteers from three separate CHMI studies [21,22]; at dC+35 for AMA1 vaccinees (n = 9) [21]
and non-sterilely protected ME-TRAP vaccinees (n = 11) [22]; from 40 naturally-exposed immune adults from Kilifi, Kenya; and 59 malaria-naı̈ve UK
adults (prior to immunization or CHMI). (C) Anti-AMA1 serum IgG responses for each group as in panel A. (D) Individual and median anti-AMA1 serum
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Serum from adults living in Kenya was collected during adult
cross-sectional surveys between 2006 and 2008 from the villages
surrounding the Chonyi area in Kilifi, Kenya which experiences
moderate malaria transmission with an entomological inoculation
rate (EIR) of 10–100 infective bites/person/year [30]. These
adults are considered to have substantial naturally-acquired
immunity as evidenced by the decline in clinical episodes of
malaria with age [31]. Scientific and ethical approvals for the
Kenyan serum samples were granted by the Kenya National
Scientific and Research Ethics Committees respectively, SSC No.
1131.
Vaccine Antigens
The composition of the bi-allelic vaccine inserts for MSP1 [32]
and AMA1 [33,34] used in the ChAd63 and MVA vaccine vectors
have been previously described. In the case of AMA1, a bivalent
transgene was optimized to consist of the 3D7 and FVO strain
alleles fused in tandem; whilst for MSP1 an insert was designed
comprising both the 3D7/MAD20 and K1/Wellcome alleles of
the dimorphic 42 kDa C-terminal region (MSP142/sequence
blocks 16+17) fused in tandem and preceded by the naturally
conserved regions of MSP1 sequence (blocks 1, 3, 5 and 12). The
MSP142 region is composed of an N-terminal 33 kDa region
(MSP133, block 16) followed by a C-terminal 19 kDa region
(MSP119, block 17). In the case of ME-TRAP, the construct
consists of the T9/96 allele of P. falciparum TRAP fused to a
multi-epitope (ME) string [35].
ELISA Antigens
The ELISA antigens used in this study have been previously
described [19,20]. Unless otherwise stated, proteins representing
the 3D7 allele of the antigen were used. Briefly, recombinant
MSP119 (ETSR = 3D7/MAD20 allele or QNKG = K1/Wellcome
allele) was produced in and purified from Escherichia coli as a
soluble glutathione S-transferase (GST) fusion protein [32].
Previous data have shown negative responses against GST control
protein in serum analysed in these clinical trials. Recombinant
3D7 AMA1 protein was a kind gift from Dr Chetan Chitnis
(ICGEB, New Delhi, India) and FVO AMA1 was a kind gift from
Dr Mike Blackman (NIMR, London, UK) [33].
Total IgG ELISA
Standardized ELISAs were conducted according to previously
described protocols for both MSP119 and AMA1 [19,20,36].
Briefly, a reference standard human serum sample for each test
antigen (with a relatively high antigen-specific response) was
serially diluted to generate a standard curve on each ELISA plate.
This standard sample was assigned a value in arbitrary ELISA
units (AU), defined as the dilution giving an optical density at
405 nm (OD405) = 1.0. The standard curve was then used to
convert absorbance values of individual test sera (diluted to fall
within the linear range of the standard curve) into AU (Gen5
ELISA software v1.10, BioTek, UK). The limit of detection in
both ELISA assays was 10 AU, and we assigned the AU value of
1.0 for any test samples with less than 10 AU. Any values more
than 10 AU are considered as positive responses in the analyses
reported here.
IgG Antibody Avidity ELISA
IgG antibody avidity was assessed by sodium thiocyanate
(NaSCN)-displacement ELISA. The assays were performed
exactly as for total IgG except sera were individually diluted in
Casein block solution (Pierce, UK) (using previously measured
total IgG ELISA AU titers) to a level calculated to give an
OD405 = 1.0, and plated at 50 mL/well in 16 wells of a 96 well
plate. Following incubation and washing, an ascending concen-
tration of the chaotropic agent NaSCN was added in duplicate
wells (50 mL per well) down the plate (0 to 7 Molar (M) NaSCN).
The NaSCN gradient was prepared beforehand by diluting an
8 M stock solution (made using water) into PBS. Plates were
incubated for 15 min at room temperature (RT) before washing
and development as for total IgG. The intercept of the OD405
curve for each sample with the line of 50% reduction of the OD405
in the NaSCN-free well for each sample (i.e. the concentration of
NaSCN required to reduce the OD405 to 50% of that without
NaSCN = IC50) was used as a measure of avidity.
Antibody Isotype ELISA
Antibody isotype ELISAs were performed exactly as for total
IgG except sera were individually diluted 1:100 in Casein block
solution and 50 mL added to duplicate wells of six 96 well plates
(one for each isotype analysis). After incubating for 2 h the plates
were washed and the following secondary antibodies added (one
per plate) at 1:1000 dilution, 50 mL per well, in Casein block
solution: biotin-conjugated mouse anti-human IgG1 Fc (clone
HP6070) (Life Technologies, UK); biotin-conjugated mouse anti-
human IgG2 Fc (clone HP6002) (Life Technologies, UK); biotin-
conjugated mouse anti-human IgG3 (clone HP6050) (Sigma, UK);
biotin-conjugated mouse anti-human IgG4 (clone HP6025)
(Sigma, UK); alkaline phosphatase-conjugated goat polyclonal
anti-human IgA a-chain (Sigma, UK); and biotin-conjugated goat
polyclonal anti-human IgM m-chain (Sigma, UK). After 1 h, all
the plates were washed before addition of 50 mL per well
ExtrAvidin alkaline phosphatase (Sigma, UK) diluted 1:5000 in
Casein block solution (to all plates except IgA, to which blocking
solution only was added). After 30 min, all plates were washed
again before development as per the total IgG ELISA. Blank wells
and internal development controls were included on each plate.
When coating the plates with recombinant MSP119 or AMA1
antigen, a number of controls (2 wells per control, 50mL per well)
were included on each plate. Instead of coating with recombinant
malaria protein, these controls wells were coated instead with
native human IgG1, IgG2, IgG3 and IgG4 (AbD Serotec, UK) at
2 mg/mL in PBS; or a hyperimmune Kenyan adult serum sample
diluted 1:10000 in PBS. During the ELISA, these wells were filled
with Casein block solution during the steps where test sera were
added to the rest of the plate. In the case of the MSP119 ELISAs,
further controls included the addition of epitope-matched mono-
clonal antibodies (mAbs) in the place of test sera (again 2 wells per
control) at 0.2 mg/mL in Casein block solution. These mAbs were
against the e9 epitope of P. falciparum MSP119 and possessed the
IgG responses are shown for AMA1 vaccinees at the peak after the MVA boost (open symbols, n = 13) [20,21] and at dC+35 following CHMI (closed
symbols, n = 9) [21]; at dC+35 for 18 infectivity control volunteers from three separate CHMI studies [21,22]; at dC+35 for MSP1-only vaccinees (n = 8)
[21]; from 50 naturally-exposed immune adults from Kilifi, Kenya; and 19 malaria-naı̈ve UK adults (prior to immunization or CHMI). (E) The fold-change
in IgG titer from dC21 (d71) to dC+35 (d107) is reported. Individual responses and geomean are shown, with symbol colouring according to group in
panels A and C. The limit of detection in both ELISA assays was 10 AU (dashed horizontal line), and we assigned the AU value of 1.0 for any test
samples with less than 10 AU. Any values more than 10 AU are considered as positive responses. *P,0.05 (Wilcoxon matched-pairs signed rank test).
doi:10.1371/journal.pone.0107903.g001
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human IgG1 [37], IgG3 (Llewellyn et al., in preparation) or IgA1
[38] Fc regions [a kind gift from Prof Richard Pleass, Liverpool
School of Tropical Medicine, Liverpool, UK]. Each of the above
control reagents was used to confirm the specificity of the isotype-
specific secondary antibodies, and in order for an assay to pass
quality control analysis, each control was required to give a
positive signal for the relevant secondary antibody, and no
response above background to the others (data not shown). During
the development of this assay, some secondary antibody reagents
did not show sufficient isotype-specific reactivity against these
internal controls, and thus were replaced with alternative reagents
(data not shown).
Assay of Growth Inhibitory Activity (GIA)
GIA was assessed as previously described [19,39] with a
standardized assay using purified IgG. Briefly, each test IgG
(10 mg/mL in a final test well) was incubated with synchronized
P. falciparum parasites for 48 h and relative parasitemia levels
were quantified by biochemical determination of parasite lactate
dehydrogenase.
Statistical analysis
Data were analysed using GraphPad Prism version 5.04 for
Windows (GraphPad Software Inc., California, USA) and non-
parametric analyses. To compare responses between selected time-
points in a group a Wilcoxon matched-pairs signed rank test was
used. Spearman’s rank correlation was used to analyse correla-
tions. Statistical significance was considered at P#0.05.
Results
Impact of CHMI on vaccine-induced antibody responses
We have previously reported the induction of antigen-specific
antibody responses following ChAd63-MVA immunization. In
these Phase I/IIa clinical trials, healthy UK adults were
immunized with the viruses encoding the MSP1, AMA1 or ME-
TRAP antigens either alone or co-administered in various
combinations [19–22] (Figure S1). In the Phase Ia safety and
immunogenicity trials (Figure S1A), antibody responses against the
MSP119 and AMA1 antigens were shown to peak 4 weeks after the
MVA boost (nominal trial day 84) [19,20]. In the Phase IIa CHMI
studies where volunteers were exposed to five infectious mosquito
bites harbouring 3D7 clone P. falciparum parasites, volunteers
were typically challenged 16 days after the MVA boost (Figure
S1B). Volunteers, who did not exhibit sterile protection, typically
developed microscopically patent blood-stage parasitemia within
9–14 days at which point they were drug-treated [21]. Here we
report on the impact of blood-stage parasite exposure on vaccine-
induced antibody responses and on the de novo induction of
malaria-specific antibody responses in non-immunized infectivity
control volunteers (Figure S1C).
Antibody responses were monitored from the day before
challenge (dC21) in volunteers receiving ChAd63-MVA immu-
nization encoding MSP1 alone, AMA1 alone, MSP1+AMA1 co-
administered or MSP1+ME-TRAP co-administered (Figure 1A
and Figure S2). dC21 is plotted as nominal study day 71 (given
CHMI occurred on average across all volunteers 16 days after the
MVA booster immunization on day 56). dC21 total IgG
responses in vaccinees against MSP119 and AMA1 have been
previously reported [21] and are shown here for completeness. In
two separate Phase IIa challenge studies (called VAC037 and
VAC039 – Figure S2 and Figure 1A respectively), serum total IgG
responses against MSP119 tended to decline in MSP1 vaccinees up
until the point of diagnosis (perhaps due to removal of antibody
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from circulation that binds to MSP1 antigen), but showed a
significant increase at the first follow-up visit after drug treatment
(dC+35/d107), P= 0.02 (Wilcoxon matched-pairs signed rank
test, n= 11 data pooled from both studies) (Figure 1A, B and
Figure S2). Very similar results were observed in volunteers
immunized with MSP1+AMA1 or MSP1+ME-TRAP (Figure 1A),
although initial anti-MSP119 antibody responses were lower given
immune-interference following vaccine co-administration, as
previously reported [21]. One out of nine volunteers immunized
with MSP1+AMA1 showed sterile protection [21]. The results for
this volunteer, who experienced no detectable blood-stage malaria
infection, are plotted separately (Figure 1A, green dashed line). In
agreement with the absence of blood-stage parasite exposure,
there was no boosting following exposure and the anti-MSP119
IgG response declined over time. Overall, across all infected MSP1
vaccinees (n= 29), blood-stage parasite exposure led to a 1.9 fold
increase (geometric mean, 95% CI: 1.3–2.7) in the anti-MSP119
IgG antibody titer at dC+35 (Figure 1E).
In the case of the control volunteers (Figure S1C) [21], almost
all became sero-positive against the MSP119 antigen, with 5/6 in
the first study (Figure S2) and 4/6 in the second study (Figure 1A)
showing detectable IgG responses at dC+35. Pooling these data
with more control volunteers from a third CHMI study [22],
showed 14/18 volunteers with anti-MSP119 responses at dC+35
(Figure 1B). Sero-positivity against MSP119 tended to be slightly
improved in volunteers previously immunized with AMA1 alone
(Figure 1A, B), with 9/9 volunteers showing positive IgG responses
at the same time-point. In contrast, volunteers receiving prior
immunization with the pre-erythrocytic antigen ME-TRAP alone
[22], showed a similar rate of sero-positivity to the controls, with
9/11 infected volunteers having measurable responses (Figure 1B).
Similar results were noted for AMA1 vaccinees. Volunteers
previously immunized with this antigen and exposed to blood-
stage parasites showed higher antibody responses at the dC+35
time-point (Figure 1C, D), and again, no boosting was observed in
the one protected volunteer co-immunized with MSP1+AMA1
(Figure 1C). Across all infected AMA1 vaccinees (n= 17), blood-
stage parasite exposure led to a 1.8 fold increase (geometric mean,
95% CI: 0.9–3.8) in the anti-AMA1 IgG antibody titer at dC+35
(Figure 1E). In the case of the control volunteers and those
immunized with MSP1 alone or MSP1+ME-TRAP, responses
were on average marginal and just above the limit of detection of
the assay (Figure 1C). In an analysis of 18 controls volunteers
across three separate CHMI studies, only 7/18 showed sero-
positivity at the dC+35 time-point, and only 4/8 following prior
immunization with MSP1 (Figure 1D). The induction of de novo
antibody responses against AMA1 thus appeared weaker in
comparison to MSP119.
Finally we compared these responses to those observed in sera
taken from a cross-sectional bleed from naturally-exposed immune
Figure 2. Assessment of functional GIA post-CHMI. (A) In vitro GIA of purified IgG was assessed at 10 mg/mL against 3D7 clone P. falciparum
parasites. Individual data and medians are shown for each vaccinated or control group at the dC21 and dC+35 time-points (n= 8–12). Pre-
immunization (d0) sera were either tested individually or pooled (n= 7). Responses .20% are typically regarded as positive. (B) Relationship between
GIA and anti-AMA1 serum IgG responses measured by ELISA. Results for volunteers immunized with ChAd63-MVA AMA1 are shown on dC21 (before
CHMI) and dC+35 (after CHMI). Non-linear regression curve is also shown (n= 19). The level of AMA1 antibody measured in this ELISA assay that gave
50% GIA (EC50, dashed black line) was 7294 AU (95% C.I. = 3981–13362).
doi:10.1371/journal.pone.0107903.g002
ChAd63-MVA and CHMI Humoral Immune Responses
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e107903
Figure 3. Assessment of IgG avidity following vaccination, CHMI and natural exposure. Avidity of serum IgG responses was
assessed by NaSCN-displacement ELISA and is reported as the molar concentration of NaSCN required to reduce the OD405 to
50% of that without NaSCN (IC50). Where samples at specific time-points tested negative for antigen-specific total IgG responses by ELISA or
these responses were too low to analyse, the avidity is not reported. Individual responses are shown, plus the median of the positive samples (i.e.
those with a detectable antigen-specific response in the total IgG ELISA that enabled assessment for avidity). (A) Anti-MSP119 responses in the
VAC037 Phase Ia clinical trial [19] following ChAd63 MSP1 priming immunization (at d28, d56 and d90) or following the MVA MSP1 boost (d84 and
d140). (B) Anti-AMA1 responses in the VAC036 Phase Ia clinical trial [20], reported as in panel A. (C) Anti-MSP119 responses in the VAC039 Phase IIa
clinical trial [21] following ChAd63 MSP1 priming immunization (at d28 and d56); or following the MVA MSP1 boost (dC21, equivalent to d84 in panel
A); or following CHMI at day of diagnosis, dC+DoD, or at first follow-up post-drug treatment, dC+35. (D) Anti-AMA1 responses in the VAC039 Phase IIa
clinical trial [21], reported as in panel C. In panels A–D, n= 2–12 depending on sample availability for each tested time-point. (E) Individual and
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adults residing in Kilifi district, on the east coast of Kenya.
Responses measured to both antigens following many years of
natural exposure showed a broad spread in terms of magnitude,
with the strongest responses similar to those induced by ChAd63-
MVA immunization (Figure 1B, D).
Associations between IgG antibody responses to MSP119
and AMA1 and CHMI outcome measures
Having measured antibody responses post-CHMI in vaccinees
and controls, we next sought to assess associations between the
impact of CHMI on antibody responses and other outcome
measures (Table 1). In the case of MSP119, there was a strong
significant correlation (P= 0.006) between the pre-challenge IgG
antibody titer at dC21 in volunteers receiving the MSP1 vaccine
(either alone or co-administered) and the post-challenge IgG titer
measured at dC+35. A similar trend was observed in AMA1
vaccinees, but did not reach significance (P= 0.06). However,
there was no clear correlation between the dC21 titer and
subsequent fold-change in IgG titer (as shown in Figure 1E) for
either antigen, nor was there any relationship between the fold-
change in IgG titer and the time to blood-stage infection diagnosis
by thick-film microscopy or the level of parasitemia, measured as
parasites/mL blood by quantitative PCR (qPCR), at the time of
diagnosis.
In the case of the unimmunized control volunteers and ME-
TRAP vaccinees (both groups being ‘blood-stage antigen naı̈ve’),
there was a significant positive correlation between their dC+35
IgG titers against MSP119 and time-to-diagnosis as well as
parasitemia at diagnosis, thus suggesting the degree of parasite
exposure strongly influences antibody induction against this
antigen. In contrast, this was not observed in the AMA1 vaccinees,
in agreement with the above observations that prior exposure to
the blood-stage AMA1 antigen is affecting the de novo immuno-
logical response to MSP119. As outlined above, de novo responses
to AMA1 were much weaker in the controls and MSP1 vaccinated
individuals, and similar relationships with CHMI outcome
measures were not observed against this antigen.
We also assessed cross-reactivity by ELISA of these sera against
other alleles of MSP119 and AMA1. Both the MSP1 and AMA1
viral vectored vaccines expressed bi-allelic constructs. In the case
of MSP1 both major alleles of MSP119 were encoded [32], which
differ by 4 amino acids – the ETSR allele (present in the 3D7
clone parasite used for CHMI studies) as well as the QKNG (or
K1/Wellcome) allele. In the case of AMA1, two versions of the
ectodomain were expressed [33] – the 3D7 and FVO alleles which
differ by 24 amino acids. Following vaccination only (dC21 sera
in the Phase IIa trials), there was a highly significant correlation
between ELISA responses against recombinant proteins for both
alleles of both antigens (Table 2). This was in agreement with
previous reported observations from the Phase Ia trials [19,20]
and similar trials of protein-based vaccines [40]. Following CHMI,
and exposure to only 3D7 clone parasites, this highly significant
correlation was maintained for both antigens in the vaccinated
volunteers. In the case of the control volunteers, who only
experienced 3D7 clone infection during the CHMI study,
responses post-CHMI at dC+35 to the homologous ETSR allele
of MSP119 still showed a strong significant correlation with those
measured against the heterologous QNKG allele, but the
relationship was slightly weaker in comparison to the vaccinees
who had been previously immunized against both. A similar result
was observed in the immune sera from the Kenyan adults where a
strong correlation in ELISA reactivity was observed against both
alleles of MSP119 and AMA1 in agreement with other studies [41].
Impact of CHMI on in vitro GIA
Having shown the impact of CHMI on vaccine-induced and
de novo IgG antibody responses, we also sought to assess the
impact on functional activity. In vitro GIA was measured against
challenge homologous 3D7 clone parasites using 10 mg/mL
purified IgG from the dC21 and dC+35 time-points. The dC21
data have been previously reported [21] and are included here for
ease of comparison. Following CHMI, there was no change in the
average levels of GIA between dC21 and dC+35 (the peak of the
serum antibody response) in any group (Figure 2A). No measur-
able GIA was induced in the controls following CHMI. A small
handful of volunteers showed increased responses, in particular
purified IgG from two AMA1 vaccinees showed 83% and 99%
GIA at dC+35. The levels of GIA in the purified IgG from all the
AMA1 vaccinees also showed a strong relationship with anti-
AMA1 IgG antibody titer (Figure 2B).
Analysis of anti-MSP119 and -AMA1 antibody avidity
following vaccination, CHMI and natural exposure
We next assessed the avidity of the anti-MSP119 and -AMA1
antibodies using a NaSCN-displacement ELISA. Initially this was
measured in serum from volunteers in the Phase Ia clinical trials of
these vaccines [19,20]. Responses were assessed at d28, d56 and
d90 for those receiving ChAd63 MSP1 or AMA1 vaccines alone,
and at d28, d56, d84 and d140 for those that were also boosted
with MVA encoding the same antigen at d56 (Figure S1A). For
MSP119 the median avidity of the antibodies tended to increase
slightly over time following ChAd63 MSP1 priming (from d28 to
d90) (Figure 3A). Administration of the MVA MSP1 boost at day
56 led to an increase in IgG avidity, with no further increase
evident over time as assessed out to d140. In contrast for AMA1,
there was relatively little, if any, change over time following the
prime (Figure 3B). After the MVA AMA1 boost at day 56 there
was an increase in median avidity, however, the change in NaSCN
IC50 was extremely small in comparison to that observed with
MSP119.
In the Phase IIa challenge study, we similarly measured IgG
avidity after vaccination and also after blood-stage parasite
exposure [21]. In these new groups of volunteers, we observed
similar changes in avidity measured after the MVA boost
vaccinations, as to those seen previously in the Phase Ia trials.
When comparing day 56 with dC21 (equivalent to day 84 in the
Phase Ia studies), there was a significant increase in avidity for
MSP119 (P= 0.03, Wilcoxon matched-pairs signed rank test,
n= 9) (Figure 3C) and another very small increase in the median
IC50 for AMA1 (Figure 3D). Following CHMI, IgG avidity was
measured on the day of malaria diagnosis (dC+DoD) and 35 days
post challenge (dC+35). There was no change in the avidity of the
antibodies when comparing the post-challenge time-points with
median anti-MSP119 serum IgG avidity responses are shown for MSP1-only vaccinees at the peak after the MVA MSP1 boost (‘‘Vaccine’’, n= 12) and at
dC+35 following CHMI (‘‘Vaccine+CHMI’’, n= 11) [21]; at dC+35 for 14 infectivity control volunteers from three separate CHMI studies (‘‘CHMI’’) [21,22];
and from 19 naturally-exposed immune adults from Kilifi, Kenya. (F) Individual and median anti-AMA1 serum IgG avidity responses are shown for
AMA1-only vaccinees at the peak after the MVA AMA1 boost (n= 9) and at dC+35 following CHMI (n= 9) [21]; and for 3 infectivity control volunteers
and 20 naturally-exposed immune adults from Kilifi, Kenya. *P,0.05 (Wilcoxon matched-pairs signed rank test).
doi:10.1371/journal.pone.0107903.g003
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dC21, despite parasite exposure and boosting of the IgG titers
(Figure 1).
We next assessed the avidity of antibodies against MSP119 and
AMA1 in 20 adults from the cohort in Kilifi, Kenya as well as in
the infectivity control volunteers from the CHMI studies. The
antigen-specific IgG in the Kenyan adults showed a much greater
range of avidity in comparison to the vaccinees, ranging from 0–
5 M for both MSP119 (Figure 3E) and AMA1 (Figure 3F);
indicating that much higher avidities can be achieved following
natural exposure (potentially a reflection of life-long multiple
exposures) as opposed to vaccination and a single infectious
exposure in the context of CHMI. Few volunteers had anti-AMA1
IgG responses post-CHMI, but the few that did showed similar
avidities to the vaccinees (Figure 3F). In contrast, most of the
CHMI controls became sero-positive to MSP119, and these serum
IgG responses showed relatively low avidity in comparison to
vaccination (Figure 3E).
Finally we assessed for any relationships between antigen-
specific IgG avidity and total IgG titer as measured by these
ELISA assays. Across all the groups studied – irrespective of
vaccination status, or parasite exposure via CHMI or natural
infection, we observed no significant correlations between IgG
avidity and titer (Table 3), suggesting these assays measure
independent attributes of the antibody response.
Analysis of anti-MSP119 and -AMA1 antibody isotypes
following vaccination, CHMI and natural exposure
Similar to the IgG avidity analysis, we also examined the serum
antibody isotype profile to both antigens by ELISA. Initially this
was measured in serum from volunteers immunized with ChAd63-
MVA MSP1 or AMA1 in the Phase I/IIa clinical trials of these
vaccines [19–21]. Results were comparable across the cohorts of
volunteers immunized with the same vaccines in the different
clinical trials (open versus closed symbols, Figure 4A, B). Following
the MVA boost, IgG1 and IgG3 were the predominant IgG
isotypes against both MSP119 and AMA1. IgG2 was detectable in
a minority of volunteers, and no IgG4 response was detected
against either antigen. IgA and IgM responses were also detected
to both antigens in the majority of volunteers (Figure 4A, B).
Exposure to 3D7 clone blood-stage parasites in the context of
CHMI showed minimal impact on the isotype profile during
infection (assessed at the diagnosis time-point) or following
treatment (dC+35). There were notable increases in the levels of
IgG1, IgG3 and IgM in both the MSP1 and AMA1 vaccinees by
dC+35 (Figure 4A, B).
We also assessed the isotype profile of anti-MSP119 and -AMA1
antibodies in the infectivity control volunteers from the UK who
were challenged across three different mosquito bite CHMI
studies. Similar to the vaccinees, following the low-density blood-
stage infection, control volunteers who became sero-positive to
MSP119 showed predominantly IgG1 responses with some IgG3
(Figure 5A). There was no detectable IgG2 or IgG4, and only a
few volunteers with low-level IgA. Interestingly, almost all
volunteers showed an IgM response, stronger than that seen in
the MSP1 vaccinees and in line with a primary humoral response
to this antigen. A similar analysis of the naturally-immune adults
from Kilifi, Kenya showed largely similar results, with a pre-
dominance of IgG1 and IgG3; no detectable IgG2, IgG4 or IgA;
and low-level IgM (Figure 5A).
Results with AMA1 were consistent with those observed for
MSP119. As noted earlier in the total IgG ELISAs (Figure 1D), few
control volunteers showed detectable responses. In agreement with
the less-sensitive isotype ELISAs, no IgG isotype responses were
detected following CHMI alone, however, the majority of
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Figure 4. Assessment of antibody isotype profiles following vaccination and CHMI. Isotype profiles of serum antibody responses
were assessed by ELISA. (A) Anti-MSP119 responses in the VAC037 Phase Ia clinical trial (open symbols) [19] and the VAC039 Phase IIa clinical trial
(closed symbols) [21]. Responses are shown at baseline (d0); following ChAd63 MSP1 priming immunization (d28); following the MVA MSP1 boost
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volunteers possessed serum anti-AMA1 IgM consistent with the
primary response to infection (Figure 5B). The same analysis of the
naturally-immune adults from Kilifi, Kenya again showed a pre-
dominance of IgG1 with lower levels of IgG3 and IgA; no
detectable IgG2 or IgG4; and low-level IgM (Figure 5B).
Finally we assessed the relationship between the dominant IgG1
and IgG3 isotype responses against both antigens in the different
populations. In the case of MSP119, following vaccination alone
(dC21) and vaccination plus 3D7 clone parasite exposure in the
context of CHMI (dC+35), immune sera showed a significant
positive correlation between IgG1 and IgG3 antibodies (P= 0.04,
rs = 0.50, n= 17; P= 0.02, rs = 0.70, n= 11, respectively) (Fig-
ure 6A). A similar observation was seen following CHMI only in
the infectivity controls (P= 0.001, rs = 0.79, n= 18). Interestingly,
a very contrasting relationship was observed in the Kenyan adults,
where a very dichotomous response was observed – immune sera
showed strong IgG1 or IgG3 responses, but not both (Figure 6A).
In the case of AMA1, as for MSP119, we observed a significant
correlation between IgG1 and IgG3 responses following vaccina-
tion (P= 0.03, rs = 0.60, n= 13). Following CHMI, this relation-
ship was not as strong and did not reach significance (P= 0.11,
rs = 0.58, n= 9) Similar to MSP119, a different result was also
observed in the Kenyan adults with all showing detectable anti-
AMA1 IgG1 responses, but only about half of these also positive
for anti-AMA1 IgG3. Overall these results suggest a propensity of
the ChAd63-MVA viral vectored vaccines to induce a balanced
IgG1 and IgG3 response, in comparison to parasite exposure
where more skewed IgG isotype profiles appear evident.
Discussion
This study has explored the impact of CHMI on qualitative and
quantitative vaccine-induced antibody responses against two
blood-stage malaria antigens – MSP119 and AMA1. Initial data
showed that a single CHMI (whereby all but one volunteer
developed blood-stage infection) led to increased serum IgG
antibody responses against both antigens in vaccinees post-
infection and drug-treatment. On average, serum IgG responses
to both antigens showed a similar 2-fold increase by 35 days post-
CHMI. This kinetic and short-term re-boosting is consistent with
modest incremental increases in antibody levels with age that are
observed in repeatedly exposed individuals [42,43], and also
consistent with boosted memory B cell responses previously
reported in these Phase IIa studies [27]. The significant
relationship between pre- and post-challenge serum IgG titers
for both antigens agrees with the fairly similar fold-change in
antibody titers observed across all vaccinees, and suggests a fairly
consistent impact of low-density blood-stage parasite exposure on
B cell re-stimulation. Other Phase IIa CHMI studies of blood-
stage vaccine candidates (protein-in-adjuvant or virosomes) have
reported post-challenge antibody responses that are not boosted
[44–46] or decline following CHMI [11]. In contrast, another
Phase IIa study of a poxvirus-based vector (NYVAC) encoding
seven P. falciparum malaria antigens reported an increase in sero-
reactivity to MSP1 and AMA1 in vaccinees post-challenge [47],
similar to that observed here in ChAd63-MVA vaccinees. In
contrast to protein vaccines, these results may suggest that viral
vector vaccination primes an antibody response that is better
suited to boosting by natural malaria exposure, perhaps due the
improved elicitation of cellular immune responses by viral vectors
[17,20,28] that may provide improved CD4+ T cell help to B cells
responding to the infection. We have previously characterized in
detail the T cell responses induced by these vaccines following
vaccination and CHMI [28], and on-going work is seeking to
assess peripheral CD4+ T cells with a T follicular helper (Tfh) cell-
like phenotype [48].
As previously observed in our study of B cell responses [27],
following CHMI of blood-stage malaria-naı̈ve control volunteers,
almost all became sero-positive in terms of anti-MSP119 IgG.
Similar results have been reported in travellers returning with P.
falciparum infection [49]. Development of these responses was
strongly associated with the level of parasitemia at diagnosis,
suggesting a relationship with the amount of MSP1 antigen
exposure and/or the more abundant nature of this surface protein
in comparison to the micronemal AMA1 antigen. MSP119 sero-
positivity in AMA1 vaccinees was also more pronounced,
suggesting that pre-existing immune responses against a blood-
stage antigen (in this case either anti-AMA1 antibodies or AMA1-
specific CD4+ T cell help) may aid the induction of de novo
responses against other blood-stage antigens. A previous report
from a different series of CHMI studies suggested PfEMP1 and the
R2 region of glutamate-rich protein (GLURP) may be similarly
immuno-dominant to MSP119, whilst responses against the R0
and R1 regions of GLURP, MSP3 C-terminus, F2 region of
EBA175, and RIFINs are more akin to those observed against
AMA1 [50].
Despite the induction of these de novo responses in malaria-
naı̈ve controls, and boosting of vaccine-induced responses in the
MSP1 and AMA1 vaccinees, there was no significant impact on
overall functional GIA activity of purified IgG assessed at the peak
of the responses 35 days post-CHMI. Negative GIA in the serum
of control volunteers after CHMI is consistent with a previous
Phase IIa study report [44], although the study in returning
travellers suggested some functional activity due to MSP119
responses measured using an alternative assay with a chimeric
parasite [49]. In the case of the AMA1 vaccinated group, GIA was
associated with anti-AMA1 ELISA titer both pre- and post-CHMI
consistent with the notion that the measurable activity was due to
these antibodies as opposed to de novo responses against other
blood-stage parasite antigens. A previous AMA1 vaccine study in
Mali suggested that malaria-specific non-AMA1 IgGs can interfere
with GIA mediated by AMA1-specific IgGs [51]. In our case
however, there was no obvious induction of de novo antibodies
against other antigens during the CHMI that interfered with
AMA1-associated GIA. Nevertheless, given the overall low levels
of GIA induced by ChAd63-MVA MSP1 or AMA1 immunization
(a reflection of moderate IgG concentrations that are on average
about 40 mg/mL antigen-specific IgG in humans – as reported
and discussed elsewhere [19,20,39]), our on-going clinical work
has assessed the merits of combining viral vectored and protein-in-
adjuvant vaccines [17,34,52,53] against AMA1 aiming to achieve
even higher concentrations of antigen-specific IgG. These results
and a quantitative analysis of antigen-specific IgG concentrations
are reported elsewhere [54].
The role of IgG avidity in protection against the blood-stage
merozoite remains a poorly understood attribute of antibody
function. The NaSCN-displacement ELISA employed here
represents a relatively crude measure of the overall avidity (sum
(d84 in the Phase Ia trial or dC21 in the Phase IIa trial); or following CHMI at day of diagnosis, dC+DoD, or at first follow-up post drug treatment, dC+
35. (B) Anti-AMA1 responses in the VAC036 Phase Ia clinical trial [20] and VAC039 Phase IIa trial [21], reported as in panel A. In all panels, individual
and median responses are shown, n = 4–13 depending on sample availability for each tested time-point.
doi:10.1371/journal.pone.0107903.g004
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Figure 5. Assessment of antibody isotype profiles following vaccination, CHMI and natural exposure. Isotype profiles of serum
antibody responses were assessed by ELISA. (A) Individual and median anti-MSP119 serum antibody isotype responses are shown for MSP1-only
vaccinees at the peak after the MVA MSP1 boost (‘‘Vaccine’’, n= 12) and at dC+35 following CHMI (‘‘Vaccine+CHMI’’, n= 11) [21]; at dC+35 for 18
infectivity control volunteers from three separate CHMI studies [21,22]; and from 20 naturally-exposed immune adults from Kilifi, Kenya. (B) Individual
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of affinities) of the polyclonal antigen-specific IgG response.
Interestingly, increased avidity was clearly evident following the
MVA booster vaccination for anti-MSP119 IgG responses,
whereas changes were minimal at best following the boost with
MVA-AMA1. These data would suggest substantial affinity
maturation can occur following MVA booster vaccine adminis-
tration, but this may well be antigen-dependent. A previous single
allele AMA1 protein vaccine trial in healthy Dutch adults using
three different adjuvants (Alhydrogel, Montanide ISA 720 and
AS02) showed that neither adjuvant nor vaccine dose significantly
influenced average avidity measured in the same manner as here
[55]. Indeed the reported avidities (ranging on average from 0.6–
0.9 M [55]) were only slightly lower than those observed here. In
our study, subsequent malaria exposure in vaccinated individuals
had no apparent effect on avidity for either antigen, although
interestingly malaria exposure of control volunteers gave rise to a
lower avidity anti-MSP119 response (in comparison to that
induced by vaccination), suggesting the IgG response underwent
minimal affinity maturation in this context of primary low-density
infection. In contrast, a wide range of avidities was observed for
both antigens in the sera from Kenyan adults, similar to
observations in rodent malaria models [56]. These data also
confirmed that higher avidity responses can be achieved by a
lifetime of natural exposure, although responses of these magni-
tudes were not achieved either by vaccination and/or a single
CHMI. The extent to which such a parameter contributes to
natural anti-merozoite immunity, however, is not understood.
Responses against AMA1 and MSP119 measured in this Phase IIa
vaccine trial did not, by themselves, impact on parasite multipli-
cation rates following CHMI with homologous 3D7 clone
parasites delivered by mosquito bite [21]. Given ‘avidity’ is a
term used to encompass the net contribution of antibody affinity
versus valency versus epitope density to antibody-antigen binding,
future studies may be more informative by attempting to measure
these independent contributions at the clonal level [57]. Indeed,
with regard to individual antibody affinity, the rate at which
merozoite invasion is neutralized is most likely determined by the
antibody on-rate and concentration, rather than off-rate [58].
Although an association between polyclonal antibody off-rate and
risk of disease was recently reported in an immuno-epidemiolog-
ical study of natural immunity to malaria [59], other studies of
monoclonal antibodies against merozoite antigens have suggested
rapid binding of antibody to merozoite antigens is associated with
improved neutralization of RBC invasion in vitro [60].
The analysis of serum antibody isotypes showed that ChAd63-
MVA MSP1 or AMA1 immunization in healthy UK adults
induced predominantly IgG1, IgG3, IgA and IgM against both
antigens. No role has been described for IgA in protection against
blood-stage merozoites [38], however the induction of this isotype
may be more relevant to the clinical development of the
adenovirus-MVA vaccine platform against mucosal pathogens
including HIV-1 [15,17]. The strong induction of the cytophilic
human IgG1 and IgG3 isotypes is consistent with a viral-based
vaccine delivery platform [61,62], and would also be of relevance
to other pathogen targets, including HIV-1, where antibody-
mediated cellular effector functions or specific IgG isotypes may be
associated with protection [63]. In the context of blood-stage
malaria immunity, the interaction of IgG1 and IgG3 with
monocytes has been reported to be important for mediating
effective antibody-dependent cellular inhibition (ADCI) via
monocytes when using antibodies present in the serum of naturally
exposed individuals [64–66] or those specific for antigens such as
MSP3 or GLURP [67–69]. Indeed, IgG2 and IgG4 responses
have also been shown to interfere with the opsonizing effects of
IgG1 and IgG3 [65,70]. However, the extent to which these
activities could contribute to effective vaccine-induced immunity
in vivo in humans remains widely debated. Complicated interplay
has also been described between different antibody isotype Fc
regions, activatory and inhibitory Fc receptors on immune cells,
the complement system, and arrayed antigen within soluble
immune complexes [71,72], suggesting that elucidating specific
and median anti-AMA1 serum antibody isotype responses are shown for AMA1-only vaccinees at the peak after the MVA AMA1 boost (n= 9) and at
dC+35 following CHMI (n= 9) [21]; and for infectivity control volunteers and naturally-exposed immune adults from Kilifi, Kenya as in panel A.
doi:10.1371/journal.pone.0107903.g005
Figure 6. Correlations between anti-MSP119 and –AMA1 IgG1 and IgG3 isotype ELISA responses in different exposure populations.
Serum IgG1 and IgG3 isotype responses were assessed by ELISA against (A) MSP119 (ETSR allele) and (B) AMA1 (3D7 allele). Correlations are shown:
following MSP1 (n = 17) or AMA1 (n= 13) viral vectored vaccination only d84/dC21 sera (open circle and square symbols respectively); following
MSP1 (n= 11) or AMA1 (n= 9) vaccination followed by CHMI dC+35 sera (closed circle and square symbols respectively); following CHMI only (n= 18
for MSP119 only) in control volunteers’ dC+35 sera (closed diamond symbols); and for immune sera from Kenyan adults (n= 20; cross symbols).
doi:10.1371/journal.pone.0107903.g006
ChAd63-MVA and CHMI Humoral Immune Responses
PLOS ONE | www.plosone.org 14 September 2014 | Volume 9 | Issue 9 | e107903
roles of various antibody isotypes in effective immunity may be
particularly difficult.
With regard to vaccine-induced AMA1- and MSP1-specific
antibody isotype responses, a bivalent AMA1 protein vaccine
administered in Alhydrogel elicited predominantly IgG1 [40,73],
with very similar results for a MSP142 vaccine given in the same
manner [74]. In the aforementioned vaccine trial (in healthy
Dutch adults administered AMA1 protein formulated in three
different adjuvants), these platforms induced high levels of IgG1,
lower but similar levels of IgG3 and IgG4, and even lower but
detectable levels of IgG2 [55]. The induction by protein-in-
adjuvant vaccines of IgG2 and IgG4 may represent a fundamental
difference between these adjuvants and viral vectors, as noted
previously in comparative mouse studies [52]. Establishing vaccine
platforms that can induce specific antibody isotype profiles in
humans will likely remain relevant to on-going vaccine develop-
ment efforts against a variety of diseases. In the context of natural
malaria immunity, IgG1 and IgG3 responses against merozoite
antigens or infected RBC, including IgG1 against MSP1 and IgG3
against AMA1 [75,76], have been most often associated with
clinical protection in immuno-epidemiological studies [75,77,78],
with one report also associating IgG2 with protection [79]. Here
we observed a mixed IgG1 and IgG3 response following
vaccination with MSP1 and AMA1, which was maintained post-
CHMI. A single CHMI induced predominantly IgG1 to MSP119,
and substantial levels of IgM to both antigens in agreement with a
primary immune response. The Kenyan adults showed mixed
IgG1 and IgG3 responses against AMA1 that were more
comparable to vaccination, in contrast to MSP119 where a
dichotomous relationship was observed. Data are conflicting from
other endemic populations, but in general IgG1 and/or IgG3 are
most consistently observed for anti-AMA1 and anti-MSP119 serum
antibody responses [41,43,76,80]. Polarization towards one
isotype has been reported with increasing age (and malaria
exposure) in some studies for merozoite antigens [81], but not
others [76]. The tendency to produce IgG1 or IgG3 appears likely
to reflect a complex interplay of immune system maturity,
duration of antigen exposure and inherent characteristics of the
antigen sequence [81].
Overall these data describe complex differences in qualitative
aspects of human antibody responses against malaria antigens
depending on the means of their induction and/or exposure of the
host to the malaria parasite. Given the continued clinical
development of viral vectored vaccines for a wide variety of
diseases [15,17] and other malaria antigens [23,82,83], these data
should help to guide further immuno-monitoring studies of
vaccine-induced human antibody responses.
Supporting Information
Figure S1 Trial timelines. (A) In Phase Ia studies, the ChAd63
priming vaccination was administered on day 0 (d0) and the MVA
booster vaccination on day 56 (d56). Blood samples were taken for
exploratory immunology at the indicated time-points. (B) In Phase
IIa studies, volunteers were immunized in the same manner.
Subsequently, controlled human malaria infection (CHMI)
followed the MVA booster vaccination on average 16 days later
(range 13–25 days). Blood samples were taken at the indicated
time-points, including the day before CHMI (dC21); 35, 90 and
150 days post-CHMI (dC+35, etc.); and at the time-point of
malaria diagnosis (dC+DoD), nominally d85. (C) Phase IIa
infectivity control volunteers underwent CHMI without previous
vaccination in parallel with vaccinated volunteers. Non-protected
and control volunteers were diagnosed with microscope-patent
blood-stage malaria infection on average 10–11 days after CHMI
(dC+10/11) at which point they received anti-malarial drug
treatment [21]. The next follow-up time-point was dC+35.
(TIF)
Figure S2 Assessment of MSP119 IgG antibody responses post-
CHMI. Mean anti-MSP119 serum IgG responses were assessed
over time by ELISA and are shown for a second Phase IIa CHMI
trial [21]. Dashed vertical lines represent: day 72 (d72) = day of
CHMI; and d85 = nominal day of diagnosis. The first follow-up
time-point after CHMI = day 107 (dC+35). The data are shown
for the VAC037 trial: MSP1 vaccinees (n = 3); and infectivity
controls (n = 6). The limit of detection in the ELISA assay was 10
AU (dashed horizontal line), and we assigned the AU value of 1.0
for any test samples with less than 10 AU. Any values more than
10 AU are considered as positive responses.
(TIF)
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